1. What Is the Thyroid Cancer Market?
The Thyroid Cancer Market covers the medicines and therapies used to treat differentiated thyroid carcinoma including papillary and follicular subtypes, medullary thyroid carcinoma, and anaplastic thyroid carcinoma. The market spans the radioactive iodine ablation for differentiated thyroid cancer and the kinase inhibitors sorafenib, lenvatinib, cabozantinib, and selpercatinib. The RET inhibitor treats the RET-mutated MTC and PTC, and the BRAF-MEK combination treats the BRAF V600E anaplastic thyroid carcinoma. The differentiated thyroid cancer carries the most favourable prognosis of any solid cancer with 98 percent 5-year survival for early-stage disease. The RAI-refractory progressive differentiated thyroid cancer and the aggressive anaplastic thyroid carcinoma that progresses within weeks require the kinase inhibitor therapy. The ATC anaplastic thyroid carcinoma BRAF V600E positive subgroup treated with the dabrafenib-trametinib combination in the ROAR basket trial demonstrated 69 percent overall response rate and the nearly 1-year median overall survival. The 1-year median overall survival far exceeds the 6-month median expected without targeted treatment. This has transformed the previously universally fatal ATC for the BRAF-positive subgroup that molecular testing identifies.
2. Thyroid Cancer Market Size & Forecast
3. Emerging Technologies
- Lenvatinib SELECT Phase III trial demonstrated 18.3-month progression-free survival versus 3.6-month placebo in the RAI-refractory differentiated thyroid cancer. The multi-kinase inhibitor is now the standard treatment for the progressive RAI-refractory DTC. The 65 percent objective response rate including the complete response in 1.5 percent and the partial response in 63.2 percent supports the standard use.
- Selpercatinib LIBRETTO-001 Phase I/II trial demonstrated 64 percent objective response rate in the previously treated RET-mutated medullary thyroid carcinoma and 85 percent ORR in the treatment-naive patients. The selective RET inhibitor is now the standard for the RET-mutated MTC. The highly selective RET tyrosine kinase inhibition achieves the superior tolerability over the multi-kinase cabozantinib.
- BRAF V600E ATC treatment with dabrafenib-trametinib ROAR basket trial 69 percent response rate provides the first effective targeted therapy for the anaplastic thyroid carcinoma. The ATC carries the near-universal mortality within 6 months without the targeted BRAF-MEK blockade. The targeted blockade converts the typically fatal diagnosis to the manageable disease for the BRAF-positive minority.
- Thyroglobulin and thyroglobulin antibody surveillance monitors the differentiated thyroid cancer recurrence after the total thyroidectomy and the radioactive iodine ablation. The stimulated thyroglobulin measurement and the neck ultrasound detect the structural recurrence before the clinical manifestation. The biochemical recurrence marker enables the early detection that the structural imaging confirms.
Similar technologies are also transforming adjacent markets. Learn more in our Biopharmaceutical Market.
4. Key Market Opportunity
Substantial growth potential in the Thyroid Cancer market stems from selective RET inhibitor expansion into additional RET-altered patient populations including earlier-line use and combination approaches. Companies with approved selpercatinib and pralsetinib capturing broader RET thyroid cancer prescribing grow market penetration. A separate growth lever involves immune checkpoint combination in anaplastic thyroid cancer building on BRAF-MEK response. As RET inhibitor use expands and ATC combination therapy advances, the addressable opportunity is growing from multikinase inhibitor dominance toward selective targeted and combination therapy in molecularly defined thyroid cancers.
5. Top Companies in the Thyroid Cancer Market
The following organisations hold leading positions in the Thyroid Cancer Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Eisai
- Bayer
- Eli Lilly
- Roche
- Novartis
- Exelixis
- Bristol-Myers Squibb
6. Market Segmentation
The Thyroid Cancer Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Cancer Type | PTC FTC MTC ATC PDTC |
| By Drug Class | RET Inhibitor Multikinase Inhibitor BRAF Inhibitor RAI Checkpoint Inhibitor |
| By Mutation | RET BRAF V600E RAS |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Thyroid Cancer Market trajectory over the forecast period:
Lenvatinib SELECT Trial 18.3 vs 3.6-Month PFS in RAI-Refractory Differentiated Thyroid Cancer With 65 Percent ORR Has Established the Multi-Kinase Inhibitor as the Standard for Progressive RAI-Refractory DTC.Eli Lilly's Selpercatinib demonstrated 79% response rate in RET-mutant medullary thyroid cancer and 64% in RET-fusion-positive papillary thyroid cancer in LIBRETTO-001, establishing highly selective RET kinase inhibition as the standard of care for the 60-70% of medullary thyroid cancer patients with RET mutations. Blueprint Medicines's pralsetinib demonstrated 71% response rate in RET-mutant medullary thyroid cancer in ARROW, providing an alternative RET-selective inhibitor with similar efficacy. Both agents replaced the multi-targeted kinase inhibitors vandetanib and cabozantinib that had been associated with significant toxicity including significant hand-foot syndrome and fatigue that required dose reduction in a majority of patients.
Selpercatinib LIBRETTO-001 85 Percent ORR in Treatment-Naive RET-Mutated MTC With Superior Tolerability Over Multi-Kinase Cabozantinib Has Established the Selective RET Inhibitor as the Standard for the RET-Driven Medullary Thyroid Carcinoma.Eisai's lenvatinib demonstrated 18.3-month median progression-free survival versus 3.6 months for placebo in SELECT, establishing it as the preferred first-line kinase inhibitor for radioiodine-refractory DTC with more durable responses than sorafenib despite similar hypertension and proteinuria adverse events. The SELECT2 trial is evaluating lenvatinib in newly diagnosed locally advanced or metastatic DTC regardless of radioiodine refractoriness, potentially expanding the indication to the frontline setting before exhausting radioiodine options. Combination with pembrolizumab in LEAP-018 is being explored for patients who progress on radioiodine and first-line lenvatinib, adding immunotherapy to extend benefit beyond kinase inhibitor monotherapy.
BRAF V600E ATC Dabrafenib-Trametinib ROAR 69 Percent ORR Converting the Near-Universally Fatal Anaplastic Thyroid Carcinoma to a Manageable Disease Has Demonstrated the First Effective Targeted Therapy for the Previously Untreatable ATC for BRAF-Positive Patients.Novartis's dabrafenib combined with trametinib received tumour-agnostic FDA approval for BRAF V600E solid tumours not previously addressed by a specific indication, covering the approximately 40-70% of papillary thyroid cancers carrying the BRAF V600E mutation. The combination demonstrated 56% response rate in BRAF-mutant anaplastic thyroid cancer in a Phase 2 basket trial, transforming one of the most quickly fatal cancers with a median survival measured in weeks into one where responses lasting months or years are achievable. Anaplastic thyroid cancer responses represent among the most dramatic tumour shrinkage documented in oncology and have changed clinical practice at major thyroid cancer centres where genetic testing for BRAF before starting treatment is now mandatory.
For related market intelligence, see the Oncology Drug Market.
8. Segmental Analysis
By drug class, the tyrosine kinase inhibitor segment dominated the Thyroid Cancer Market in 2025, as Eisai's Lenvima and Bayer's Nexavar anchored treatment for radioiodine-refractory differentiated thyroid cancer, generating the largest share of advanced thyroid cancer revenue.
By mutation, the RET-altered segment is projected to register the highest growth rate through 2034, as Eli Lilly's Retevmo establishes selective RET inhibition as standard care for RET-fusion and RET-mutant medullary and differentiated thyroid cancers identified through the expanding adoption of next-generation sequencing across thyroid oncology practice.
9. Regional Analysis
Regional demand patterns across the Thyroid Cancer Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Thyroid Cancer Market in 2025, accounting for approximately 45% of global revenue, due to US premium pricing for selpercatinib, pralsetinib, and lenvatinib and the concentration of Eli Lilly, Blueprint Medicines, and Eisai commercial operations. Moreover, molecular RET testing and selective inhibitor adoption are most advanced in US endocrine oncology. In addition, anaplastic thyroid BRAF-MEK therapy is established. Regional dominance is attributed to this combination of pricing environment and targeted therapy adoption.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Thyroid Cancer Market through 2034, driven by the high thyroid cancer incidence in South Korea, China, and Japan and expanding access to targeted therapies including RET inhibitors through reimbursement. The region is also witnessing molecular testing adoption enabling RET and BRAF selection. Moreover, the large thyroid cancer patient burden sustains drug demand. The combination of these demand drivers and patient scale positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Thyroid Cancer Market was valued at USD 1.16 Bn in 2025 and is projected to reach USD 2.43 Bn by 2034, growing at a CAGR of 8.5% over the 2026–2034 forecast period.
The Thyroid Cancer Market is projected to grow at a CAGR of 8.5% from 2026 to 2034.
North America dominated the Thyroid Cancer Market in 2025, accounting for approximately 45% of global revenue, due to US premium pricing for selpercatinib, pralsetinib, and lenvatinib and the concentration of Eli Lilly, Blueprint Medicines, and Eisai commercial operations.
The leading companies in the Thyroid Cancer Market include Eisai, Bayer, Eli Lilly, Roche, Novartis, Exelixis, Bristol-Myers Squibb.
Lenvatinib select trial 18.3 vs 3.6-month pfs in rai-refractory differentiated thyroid cancer with 65 percent orr has established the multi-kinase inhibitor as the standard for progressive rai-refractory dtc.
By drug class, the tyrosine kinase inhibitor segment dominated the Thyroid Cancer Market in 2025, as Eisai's Lenvima and Bayer's Nexavar anchored treatment for radioiodine-refractory differentiated thyroid cancer, generating the largest share of advanced thyroid cancer revenue.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.